A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.
about
In Search of New Therapeutic Targets in Obesity Treatment: SirtuinsPotential Modulation of Sirtuins by Oxidative StressThe role of sirtuins in cardiac diseaseAdipose tissue NAD+ biology in obesity and insulin resistance: From mechanism to therapyAnti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.SIRTUIN 1 ACTIVATOR SRT1720 PROTECTS AGAINST ORGAN INJURY INDUCED BY INTESTINAL ISCHEMIA-REPERFUSIONSIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection.Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.Mechanisms of transcription factor acetylation and consequences in hearts.Insulin Resistance and Mitochondrial Dysfunction.Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus.SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis.SRT1720, a sirtuin 1 activator, attenuates organ injury and inflammation in sepsis.Circulating SIRT1 Increases After Intragastric Balloon Fat Loss in Obese Patients.Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [F]-2-Fluorobenzoylaminohexanoicanilide
P2860
Q26750982-025CE869-79F3-4FB8-98B5-5BEC92BC654FQ26770803-44125876-38EF-443B-8B2D-482AC6BD35E6Q27693274-CBE053FD-B508-4C2E-84C8-E57268892553Q33791807-85EC3EAB-B19F-4DE5-AB9B-39A23B889D11Q34444895-93A0D516-A317-4506-84E4-BBB3C1CBF0E2Q34538482-8D9EE20A-5DC4-4AD9-BBF5-A79A5DC86544Q36689329-C056438C-8B71-4017-92C6-8D0E5F68B4F5Q38665115-828B8EBB-C4E2-47E1-AF06-3F3FD5D9EC2AQ38905640-C1AA1E16-7C23-4B65-97A4-1EFCB036D202Q38932625-B4226A64-4E7B-4580-8881-0BD33F03DD58Q39334553-290D43C4-1E4F-46CE-B3DB-DD05FB635622Q41582070-ECDA54F7-16C9-46B0-9746-EE8DDBB3CCF2Q42362600-FCFD8C55-F1A8-47B7-AE4E-D71ECB5A3C22Q47593859-93BFBDF5-EBA0-4C71-A9C6-4EC328FE6EA4Q51297561-A8B88046-DB62-488B-8C02-70F57514776FQ58784374-AF9EC7A0-FCB6-46FA-96E6-4720447093C1
P2860
A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@ast
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@en
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@nl
type
label
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@ast
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@en
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@nl
prefLabel
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@ast
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@en
A phase II, randomized, placeb ...... subjects with type 2 diabetes.
@nl
P2093
P2860
P356
P1476
A phase II, randomized, placeb ...... subjects with type 2 diabetes
@en
P2093
Alsu Zalevkaya
Arun Baksi
Eric W Jacobson
Ethan Hoffmann
George P Vlasuk
Jonathan Haddad
Peter Elliott
Roman Stets
P2860
P356
10.1111/BCP.12327
P407
P577
2014-07-01T00:00:00Z